Mohammad Qureshi, MD
Endocrinology · Cordova, TNNPI 1104833326
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.8% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations.
Across 321 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Amgen$401
- Sanofi-aventis U.S. LLC$370
- Lilly USA, LLC$360
- Abbott$313
- Chiesi USA, Inc.$300
- plus $3K from 28 others
What the payments were for
- Speaking & faculty fees$3005%
- Food & beverage$5,06593%
- Education$351%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 74 | $1,105 |
| Amgen(2 entities) | 24 | $401 |
| Sanofi-aventis U.S. LLC | 19 | $370 |
| Lilly USA, LLC | 27 | $360 |
| Abbott | 24 | $313 |
| Chiesi USA, Inc. | 1 | $300 |
| Insulet Corporation | 20 | $292 |
| AbbVie | 18 | $266 |
| Sequel Med Tech, LLC | 4 | $227 |
| Boehringer Ingelheim | 14 | $208 |
| Merck | 17 | $189 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $155 |
| Johnson & Johnson | 11 | $144 |
| AstraZeneca | 11 | $144 |
| Nevro Corp. | 1 | $135 |
| Mannkind Corporation | 5 | $125 |
| Corcept Therapeutics | 6 | $124 |
| Medtronic(2 entities) | 6 | $87 |
| Xeris Pharmaceuticals, Inc. | 3 | $68 |
| Nalpropion Pharmaceuticals LLC | 4 | $67 |
| Currax Pharmaceuticals LLC | 4 | $65 |
| Ascensia Diabetes Care US Inc. | 2 | $40 |
| Tandem Diabetes Care, Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Radius Health, Inc. | 2 | $34 |
| Shire North American Group Inc | 2 | $33 |
| Bayer | 2 | $30 |
| IBSA Pharma Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Companion Medical, Inc. | 1 | $13 |
| Cequr Corporation | 1 | $13 |
| Lifescan, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few endocrinology providers in Tennesseeto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 304 | $457,281 |
| TrulicityDulaglutide | 239 | $373,185 |
| JardianceEmpagliflozin | 229 | $273,325 |
| MounjaroTirzepatide | 136 | $199,408 |
| Tresiba Flextouch U-100Insulin Degludec | 143 | $99,883 |
| FarxigaDapagliflozin Propanediol | 83 | $97,781 |
| JanuviaSitagliptin Phosphate | 61 | $70,113 |
| ForteoTeriparatide | 15 | $61,649 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 37 | $52,406 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $39,975 |
| JanumetSitagliptin Phos/Metformin Hcl | 36 | $36,514 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 101 | $35,772 |
| Novolog FlexpenInsulin Aspart | 122 | $29,593 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $29,445 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 195 | $27,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Forteo | $360 | $634,242390 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,105 | $490,507348 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Trijardy Xr | $208 | $323,209277 claims |
| MerckJanuvia, Janumet Xr, Janumet | $189 | $159,033134 claims |
| AstraZenecaFarxiga | $144 | $97,78183 claims |
| AbbVieSynthroid | $266 | $14,808191 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Tennesseeon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Cordova
- Kashif LatifBartlett$270K
- Manasa VeluruKingsport$1K
- Eduardo Lopez MartinezNashville$0
- Chase HendricksonNashville$0
- Lauren MozingoNashville$0
- Syeda ZaidiNashville$0
- Jennifer HewlettNashville$0
- Alvin PowersNashville$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.